0M4.F - Mersana Therapeutics, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 7.18 |
| Open | 7.12 |
| Bid | 7.94 x 0 |
| Ask | 8.05 x 0 |
| Day's Range | 7.12 - 7.98 |
| 52 Week Range | 2.80 - 8.20 |
| Volume | |
| Avg. Volume | 1 |
| Market Cap | 916.704M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.04 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.67 |
Fair Value
Related Research
GlobeNewswireMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on June 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and
Simply Wall St.Those who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127%
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
- GlobeNewswire
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit Format:Fireside ChatDate/Time:Wednesday, May 31, 2023, at 10:00 a.m. East
- GlobeNewswire
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023Advanced enrollment in Phase 3 UP-NEXT clinical trial of UpRi and Phase 1 clinical trial of XMT-1660Plan to report topline data from UPLIFT registrational trial in mid-2023; potential Biologics License Application (BLA) submission anticipated around the end of 2023Capital resources expected to support operating plan commitments into the second half of
- GlobeNewswire
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20 p.m. Eastern Time. A live webcast of this event will be available on th
- GlobeNewswire
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023. The company will host a conference call and webcast at 8:00 a.m. East
- GlobeNewswire
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the acceptance of multiple abstracts for poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place in Chicago from June 2-6, 2023. Presenta
TipRanksJ.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential
The first quarter is behind us and it has not lacked drama. Most recently, it has all been about the banking sector and fears that in the wake of multiple bank collapses, contagion could spread and spill over to impact the global financial system. However, it appears that, at least for the time being, these concerns have been addressed. But there’s still plenty of uncertainty about with inflation still high and the prospect of a recession looming. Against this shaky backdrop, how’s an investor t
ZacksBiotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
BenzingaFDA Halts Mersana's Early-Stage Cancer Trial After Patient Death
Mersana Therapeutics Inc's (NASDAQ: MRSN) Phase 1 trial of XMT-2056 has been placed on clinical hold by the FDA. This action follows the company's communication to FDA that Mersana was voluntarily suspending the trial due to a recent Grade 5 (fatal) serious adverse event (SAE) that was deemed related to XMT-2056. The SAE and its cause remain under investigation. XMT-2056 is Mersana's first Immunosynthen STING-agonist ADC product candidate to enter the clinic. Related: With Upcoming Ovarian Cance
- Reuters
UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death
Mersana Therapeutics Inc said on Monday the U.S. drug regulator had placed on hold an early-stage trial testing its experimental cancer drug after the death of a participant. The death was of a patient enrolled at the initial dose level in the dose escalation portion, the company said. The company is now focused on analyzing the death and "consider potential next steps for development,” Chief Executive Officer Anna Protopapas said in a statement.
- GlobeNewswire
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Phase 1 trial of XMT-2056 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). This action follows the company’s communication to FDA that Mersana was voluntarily suspen
- GlobeNewswire
Mersana Therapeutics Provides Statement About SVB
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana’s capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company’s capital resources is held in
Insider MonkeyMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to […]
- Simply Wall St.
Mersana Therapeutics Full Year 2022 Earnings: US$2.18 loss per share (vs US$2.41 loss in FY 2021)
Mersana Therapeutics ( NASDAQ:MRSN ) Full Year 2022 Results Key Financial Results Revenue: US$26.6m (up by US$26.5m...
- Thomson Reuters StreetEvents
Q4 2022 Mersana Therapeutics Inc Earnings Call
Q4 2022 Mersana Therapeutics Inc Earnings Call
- GlobeNewswire
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatinInitiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate, XMT-2056 Entered new research collaboration and commercial license agreement with Merck KGaA, Darmstadt, GermanyAnticipate topline data from UPLIFT registrational trial in mid-2023; potential Biologics License Application (BLA) submission anticipated around the end of 2023Conference call today at 8:00 a
- GlobeNewswire
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023. The company will host a conference call and
- GlobeNewswire
Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer
Company plans to report interim data for the combination of UpRi with carboplatin in the second half of 2023CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in
- GlobeNewswire
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
First Immunosynthen ADC product candidate enters the clinicCAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate. XMT-2056 is a system
BenzingaWith Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12. The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate. Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the
ZacksZai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?
Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- GlobeNewswire
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancerAdvance XMT-1660 and XMT-2056 Phase 1 trials Continue pursuing collaborations to maximize platform and pipeline potentialCapital resources expected to support operating plan commitments into the second half of 2024 CAMBRIDGE, Mass., Jan. 06, 202
- Simply Wall St.
Estimating The Fair Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mersana Therapeutics...
American City Business JournalsMerck KGaA inks deal worth up to $830M with Cambridge cancer biotech
Cancer firm Mersana Therapeutics has scored a collaboration deal worth up to $830 million with Merck KGaA, the German pharmaceutical giant.